Literature DB >> 11304513

Lacidipine prevents endothelial dysfunction in salt-loaded stroke-prone hypertensive rats.

P Krenek1, S Salomone, J Kyselovic, M Wibo, N Morel, T Godfraind.   

Abstract

Endothelium-dependent vasorelaxation is defective in hypertensive rats, especially in conduit arteries. In the stroke-prone spontaneously hypertensive rat, impaired endothelium-dependent vasorelaxation appears to contribute to the pathogenesis of stroke independent of blood pressure. Because treatment with lacidipine, a long-acting calcium channel blocker, protects against stroke and cardiovascular remodeling in this model, we investigated the effect of this treatment on endothelium-dependent vasorelaxation in the aorta. Stroke-prone rats were exposed to a salt-rich diet (1% NaCl in drinking water) with or without lacidipine (1 mg. kg(-1). d(-1)) for 6 weeks. A high-sodium diet (1) increased systolic blood pressure, aortic weight, and wall thickness and plasma renin activity (P<0.05); (2) markedly reduced nitric oxide (NO)-mediated, endothelium-dependent relaxation of aortic rings to acetylcholine and the sensitivity to the relaxing effect of S-nitroso-N-acetylpenicillamine, an NO donor (P<0.001); and (3) induced an elevation of preproendothelin-1 mRNA levels in aortic tissue (P<0.01) without affecting endothelial NO synthase mRNA levels. Lacidipine treatment prevented the salt-dependent functional and structural alterations of the aorta, including the overexpression of the preproendothelin-1 gene, and increased endothelial NO synthase mRNA levels in aortic tissue (P<0.01). In conclusion, lacidipine protects stroke-prone hypertensive rats against the impairment of endothelium-dependent vasorelaxation evoked by a salt-rich diet, and this effect may contribute to its beneficial effect against end-organ damage and stroke.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11304513     DOI: 10.1161/01.hyp.37.4.1124

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  8 in total

1.  Effects of amlodipine and lacidipine on cardiac remodelling and renin production in salt-loaded stroke-prone hypertensive rats.

Authors:  J Kyselovic; P Krenek; M Wibo; T Godfraind
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

Review 2.  Antioxidant effects and the therapeutic mode of action of calcium channel blockers in hypertension and atherosclerosis.

Authors:  Théophile Godfraind
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-12-29       Impact factor: 6.237

3.  Cilnidipine, a slow-acting Ca2+ channel blocker, induces relaxation in porcine coronary artery: role of endothelial nitric oxide and [Ca2+]i.

Authors:  Hok Sum Leung; Xiaoqiang Yao; Fung Ping Leung; Wing Hung Ko; Zhen-Yu Chen; Maik Gollasch; Yu Huang
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

4.  Lacidipine has antiatherosclerotic effects independent of its actions on lipid metabolism and blood pressure.

Authors:  Günay Yetik Anacak; Levent Ustünes; Ozlem Yilmaz Dilsiz; Adviye Ergul
Journal:  Vascul Pharmacol       Date:  2010-08-12       Impact factor: 5.773

Review 5.  Discovery and Development of Calcium Channel Blockers.

Authors:  Théophile Godfraind
Journal:  Front Pharmacol       Date:  2017-05-29       Impact factor: 5.810

Review 6.  Cerebral Small Vessel Disease (CSVD) - Lessons From the Animal Models.

Authors:  Muzaimi Mustapha; Che Mohd Nasril Che Mohd Nassir; Niferiti Aminuddin; Amanina Ahmad Safri; Mazira Mohamad Ghazali
Journal:  Front Physiol       Date:  2019-10-24       Impact factor: 4.566

7.  Lacidipine Ameliorates the Endothelial Senescence and Inflammatory Injury Through CXCR7/P38/C/EBP-β Signaling Pathway.

Authors:  Xing Liu; Zhuoshan Huang; Yuanyuan Zhang; Xing Shui; Fanmao Liu; Zhen Wu; Shiyue Xu
Journal:  Front Cardiovasc Med       Date:  2021-07-06

8.  Nephroprotection of lacidipine against gentamycin-induced nephrotoxicity in albino rats.

Authors:  Sahar Kamal
Journal:  J Exp Pharmacol       Date:  2010-06-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.